Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2022-11-01 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团关于对外担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the progress of external guarantees provided by Kunming Pharmaceutical Group Co., Ltd. It includes specifics about guarantee amounts, the companies involved, financial data of the guaranteed subsidiaries, and board opinions on the guarantees. The content focuses on financing guarantees and risk disclosures related to these guarantees. There is no indication that this is a full financial report, audit report, or earnings release. It is not a regulatory certification or a simple announcement of a report publication. The document fits best into the category of Capital/Financing Update (CAP) because it provides updates on the company's financing activities, specifically guarantees related to financing arrangements for subsidiaries.
2022-11-01 Chinese
昆药集团十届九次董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group regarding the approval of the company's 2022 third quarter report. It states that the third quarter report is published on the Shanghai Stock Exchange website and does not contain the actual financial data or detailed report itself. The document is short (460 characters) and serves as an announcement of the board's approval rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about the board meeting and report approval, not the Interim/Quarterly Report (IR) itself.
2022-10-24 Chinese
昆药集团2022年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2022 年第三季度报告" which translates to "2022 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management commentary for the third quarter of 2022. The document includes unaudited financial statements for the quarter ending September 30, 2022, and covers financial performance, shareholder information, and other operational details. The presence of comprehensive quarterly financial data and analysis indicates this is an Interim / Quarterly Report. It is not a brief announcement or a certification, nor is it a full annual report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2022
2022-10-24 Chinese
昆药集团十届九次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a supervisory board resolution announcement regarding the company's 2022 third quarter report. It states that the 2022 third quarter report and summary have been published on the Shanghai Stock Exchange website and that the supervisory board confirms the report's compliance and accuracy. The document itself does not contain the financial report but is an announcement of the supervisory board's opinion on the report. The document length is short (684 characters) and it references the report being published elsewhere. According to the 'Menu vs Meal' rule, this is an announcement about a report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-10-24 Chinese
昆药集团关于全资子公司获得安宫牛黄丸补充申请批件暨成为药品上市许可持有人的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement by Kunming Pharmaceutical Group Co., Ltd. regarding its wholly-owned subsidiary obtaining approval from the National Medical Products Administration for a drug license holder change for a specific drug (Angong Niuhuang Wan). The text includes details about the drug, the approval notice, the transfer agreement, and the impact on the company. It is a regulatory announcement about a licensing approval and business update rather than a financial report, earnings release, or management discussion. The document length is short (1449 characters) and it is an announcement of a regulatory approval event. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-10-20 Chinese
昆药集团关于回购注销部分限制性股票通知债权人的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Corporation regarding the repurchase and cancellation of restricted shares due to an employee's departure. It details the legal and procedural information for creditors to claim debts or request guarantees within a specified period. The content focuses on the company's share repurchase and capital reduction, notifying creditors about their rights and the process to submit claims. It is not a financial report, earnings release, or management discussion. It is a formal announcement related to the company's transaction in its own shares (repurchase and cancellation). Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length is short and it is not merely announcing a report publication but providing substantive information about the share repurchase and cancellation event.
2022-10-14 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.